Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial by Kievit, H., Muntinghe-Wagenaar, M.B., Hijmering-Kappelle, L.B.M., Hiddinga, B.I., Ubbels, J.F., Wijsman, R., Slingers, G., de Vries, R., Groen, H.J.M, Kerstjens, H.A.M., van der Wekken, A.J., Hiltermann, T.J.N.

Get full text